Latest developments in DUB inhibitors shared at Proteasome & Autophagy Congress
April 23, 2018
Almac Discovery to share latest developments in first-in-class DUB inhibitors at the 8th Proteasome and Autophagy Congress
Craigavon, N.I., UK, 23 April 2018 – Almac Discovery, a biopharmaceutical company with a key research focus in the area of deubiquitylating enzyme therapeutic discovery, has had its work recognized by an invitation to deliver a podium presentation at the 8th Proteasome and Autophagy Congress being held from 25th – 27th April in Clermont-Ferrand, France.
The conference theme is strongly aligned with Almac Discovery’s research strengths where it maintains a team of experts dedicated to research into the tractability of DUBs/USPs. Gerald Gavory, Head of Biology, will give an oral presentation on the “Discovery and development of first-in-class USP19 inhibitors” which will demonstrate the potential opportunities for the development of new therapeutics with applications in neurodegenerative and muscle wasting disorders.
Almac Discovery has developed its UbiPlex® platform for the discovery of hits to this challenging and novel class of DUB/USP targets which cover a broad range of potential clinical indications from neurodegeneration to cancer and infection. The company has a goal to spearhead the discovery of DUB based therapeutics and to broaden knowledge of this class of targets. The USP19 inhibitors which will be described demonstrate high potency in muscle cells together with exquisite selectivity and, taken together with their inactive control compounds, should prove excellent tools in unlocking the biology of USP19.
In addition, Ewelina Rozycka will present a poster covering additional deubiquitylating enzyme discovery work during the conference.
Almac Discovery (a member of the Almac Group) is a research driven discovery company dedicated to the discovery and development of novel and innovative therapeutic approaches. Almac Discovery focuses on the discovery to preclinical stage seeking to license programs early with a pharmaceutical partner for further development. Follow us on LinkedIn or visit almacgroup.com/discovery.
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organization that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organization that has organically grown over almost 50 years and now employs close to 5600 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).